Form 4: Corvus CBO Arcara Granted 100,000 Stock Options

Corvus Pharmaceuticals' Chief Business Officer, Jeffrey Arcara, was granted 100,000 stock options with an exercise price of $8.81, vesting over three years.

Summary

• Jeffrey Arcara, Chief Business Officer of Corvus Pharmaceuticals, Inc. (CRVS), was granted 100,000 stock options.
• The transaction date for the option grant was December 4, 2025.
• Each stock option has an exercise price of $8.81.
• The options vest and become exercisable in successive, equal monthly installments of 1/36th of the total shares, starting from December 4, 2025.
• Full vesting is contingent upon Mr. Arcara's continued service relationship with Corvus Pharmaceuticals.
• The expiration date for these stock options is December 4, 2035.
• Following this transaction, Mr. Arcara beneficially owns 100,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a standard compensation practice, generally viewed as a neutral to slightly positive event as it aligns management incentives with shareholder interests, without indicating immediate financial performance changes.

Positives

• The grant of stock options to the Chief Business Officer aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options provide a potential future upside for the officer, contingent on the company's stock price appreciation above the exercise price of $8.81.

Negatives

• The grant of options represents potential future dilution for existing shareholders if and when the options are exercised.
• There is no immediate cash benefit to the officer from this grant; the value is realized only if the stock price increases and options are exercised.

Risks

• The value of the stock options is subject to the future market price of Corvus Pharmaceuticals' common stock; if the stock price does not exceed the $8.81 exercise price, the options may expire worthless.
• The vesting of the options is conditional on Mr. Arcara's continued service, posing a risk of forfeiture if his employment terminates before full vesting.

Future Outlook

The stock option grant suggests an expectation of future growth and value creation for Corvus Pharmaceuticals, as the options are designed to incentivize the Chief Business Officer to contribute to the company's long-term success and stock price appreciation.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology and pharmaceutical industries, used to attract, retain, and motivate key personnel by linking their financial incentives to the company's long-term performance and shareholder value creation. This grant is consistent with typical compensation practices in the sector.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from incentivized management focused on increasing share value.
• Employees (specifically Jeffrey Arcara): Receives a significant long-term incentive tied to company performance and continued employment.

Next Steps

• The stock options will vest in 36 equal monthly installments, subject to the Chief Business Officer's continued service with Corvus Pharmaceuticals.

Key Dates

Keywords

Corvus Pharmaceuticals, CRVS, Jeffrey Arcara, Stock Options, Insider Transaction, Form 4, Executive Compensation, Biotechnology, Pharmaceuticals